Biochemistry & Analytical Biochemistry

Nicola Carella

Publications

• Research Article
  Modulation of Doxorubicin Actions in Hepatocellular Carcinoma Cells by Insulin-Like Growth Factor-I
  Author(s): Maria Grazia Refolo, Rosalba D’Alessandro, Catia Lippolis, Nicola Carella, Caterina Messa, Aldo Cavallini and Brian Irving Carr Maria Grazia Refolo, Rosalba D’Alessandro, Catia Lippolis, Nicola Carella, Caterina Messa, Aldo Cavallini and Brian Irving Carr
  
  Hepatocellular carcinoma (HCC) is typically advanced at presentation and doxorubicin is the chemotherapeutic agent most frequently used in chemoembolization. Tumor microenvironment contains many cell types, including platelets, as well as cytokines and growth factors, potentially capable of modulating doxorubicin actions. Insulin-like growth factor I (IGF1) and its receptor (IGF1-R) signaling is important in cellular proliferation and prevention of apoptosis and the acquisition of chemotherapy resistance. IGF1 is present in platelets, which have been shown to alter doxorubicin actions in HCC cells. The effects on growth and motility after IGF1 pre-treatment in doxorubicin-treated HCC cells were thus examined, as well as the IGF1-R downstream pathways, PI3/Akt and MAPK kinases. We found that IGF1 antagonized the doxorubicin-mediated decrease in cell growth and motility, as well as the .. View More»
  DOI: 10.4172/2161-1009.1000256

  Abstract PDF